Literature DB >> 12548132

Blockade of in vivo VEGF-KDR/flk-1 signaling does not affect revascularization of freely transplanted pancreatic islets.

Rene Schramm1, Jun-Ichiro Yamauchi, Brigitte Vollmar, Peter Vajkoczy, Michael D Menger.   

Abstract

BACKGROUND: The aim of this study was to analyze the role of vascular endothelial growth factor (VEGF) binding to its high-affinity receptor kinase insert domain (KDR)-containing receptor/fetal liver kinase (flk)-1 in mediating revascularization of freely transplanted pancreatic islets in vivo.
METHODS: Isolated pancreatic islets were syngeneically transplanted into dorsal skinfold chambers of Syrian hamsters. Animals were treated daily with the VEGF-KDR/flk-1 antagonist SU5416 (25 mg/kg intraperitoneally) or received vehicle for control. Intravital fluorescence microscopy and computer-assisted off-line analysis were used to study islet graft angiogenesis and revascularization during days 6, 10, and 14 after transplantation.
RESULTS: In controls, islets were revascularized within 10 to 14 days after transplantation. SU5416 treatment did not affect revascularization, inasmuch as both functional capillary density and size of revascularized endocrine tissue did not differ from that of vehicle-treated controls.
CONCLUSION: Because blockade of VEGF-KDR/flk-1 function does not affect islet revascularization, we conclude that VEGF signaling through its high-affinity receptor KDR/flk-1 is not an essential prerequisite for the process of new-vessel formation in freely transplanted islets of Langerhans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548132     DOI: 10.1097/01.TP.0000040869.19883.4A

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Better vascular engraftment and function in pancreatic islets transplanted without prior culture.

Authors:  R Olsson; P-O Carlsson
Journal:  Diabetologia       Date:  2005-02-05       Impact factor: 10.122

2.  Erythropoietin accelerates the revascularization of transplanted pancreatic islets.

Authors:  Maximilian M Menger; Lisa Nalbach; Leticia P Roma; Christina Körbel; Selina Wrublewsky; Matthias Glanemann; Matthias W Laschke; Michael D Menger; Emmanuel Ampofo
Journal:  Br J Pharmacol       Date:  2020-02-10       Impact factor: 8.739

3.  Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.

Authors:  Daniele Vicari; Kevin C Foy; Eric M Liotta; Pravin T P Kaumaya
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

4.  Pancreatic duct cells in human islet cell preparations are a source of angiogenic cytokines interleukin-8 and vascular endothelial growth factor.

Authors:  Babak Movahedi; Conny Gysemans; Daniel Jacobs-Tulleneers-Thevissen; Chantal Mathieu; Daniel Pipeleers
Journal:  Diabetes       Date:  2008-05-20       Impact factor: 9.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.